Suppliers and packagers for generic pharmaceutical drug: midodrine hydrochloride

midodrine hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-338-31	100 TABLET in 1 BOTTLE (46708-338-31)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-338-71	500 TABLET in 1 BOTTLE (46708-338-71)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-339-31	100 TABLET in 1 BOTTLE (46708-339-31)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-339-71	500 TABLET in 1 BOTTLE (46708-339-71)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-340-31	100 TABLET in 1 BOTTLE (46708-340-31)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Limited	46708-340-71	500 TABLET in 1 BOTTLE (46708-340-71)	2021-01-22
Alembic	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	214734	ANDA	Alembic Pharmaceuticals Inc.	62332-338-31	100 TABLET in 1 BOTTLE (62332-338-31)	2021-01-22

MIDODRINE HYDROCHLORIDE: KEY SUPPLIER LANDSCAPE

Last updated: February 19, 2026

This report analyzes the current landscape of Midodrine Hydrochloride suppliers. The drug, primarily used to treat symptomatic orthostatic hypotension, relies on a specialized manufacturing process. Key suppliers identified operate within a regulated environment, adhering to Good Manufacturing Practices (GMP). The market is characterized by a limited number of active pharmaceutical ingredient (API) manufacturers and a broader base of contract manufacturing organizations (CMOs) capable of final dosage form production. Understanding these supplier relationships is critical for maintaining supply chain integrity and managing costs.

WHO ARE THE PRIMARY API MANUFACTURERS FOR MIDODRINE HYDROCHLORIDE?

The primary API manufacturers for Midodrine Hydrochloride are a select group of chemical synthesis companies. These entities possess the technical expertise and regulatory compliance necessary for producing the active pharmaceutical ingredient in bulk quantities. The synthesis of Midodrine Hydrochloride involves specific chemical steps that require careful control of reaction conditions and purification processes to meet pharmaceutical standards.

Key API manufacturers include:

• Euticals S.p.A. (now part of Wockhardt): Historically a significant producer of Midodrine Hydrochloride API. Their acquisition by Wockhardt in 2016 integrated their API manufacturing capabilities into a larger pharmaceutical entity.
• Helsinn Healthcare S.A.: A Swiss pharmaceutical company that has been involved in the development and manufacturing of Midodrine Hydrochloride. Their role often extends to formulation and finished product manufacturing in addition to API supply.
• Major Pharmaceutical Ingredient Manufacturers in India and China: Several large-scale API producers in these regions are capable of manufacturing Midodrine Hydrochloride, often serving the global generic market. Specific company names are frequently dynamic due to supply agreements and market shifts, but typically include well-established players in API production for various therapeutic classes. These manufacturers must demonstrate robust quality management systems and pass regulatory audits from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

These manufacturers are critical to the availability of Midodrine Hydrochloride. Their production capacity, quality control adherence, and supply chain reliability directly impact the downstream formulation of the drug.

WHAT ARE THE KEY CHARACTERISTICS OF MIDODRINE HYDROCHLORIDE API PRODUCTION?

The production of Midodrine Hydrochloride API is defined by stringent chemical synthesis requirements and regulatory oversight. The process involves multiple synthetic steps, starting from commercially available chemical precursors. Key characteristics include:

• Multi-Step Chemical Synthesis: The synthesis pathway for Midodrine Hydrochloride typically involves several distinct chemical reactions. These steps can include amination, reduction, and salt formation. Each step requires precise control of temperature, pressure, and reagent addition to maximize yield and purity.
• Chiral Synthesis Considerations: Midodrine is a racemic mixture of two enantiomers. While the therapeutic activity is primarily associated with one enantiomer, the marketed drug is typically the racemate. Manufacturers must ensure consistent control over the stereochemistry if specific enantiomeric ratios are required, although the standard API is the racemate.
• Purification and Isolation: After synthesis, rigorous purification steps are essential to remove process impurities, residual solvents, and unreacted starting materials. Techniques such as recrystallization, chromatography, and filtration are employed to achieve the high purity required for pharmaceutical use, typically exceeding 98%.
• Salt Formation: The final step involves forming the hydrochloride salt of Midodrine. This is crucial for improving solubility and stability of the compound for pharmaceutical formulations. The process requires controlled addition of hydrochloric acid under specific conditions.
• Good Manufacturing Practices (GMP) Compliance: All API production must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory authorities like the FDA and EMA. This includes detailed batch records, validated processes, stringent quality control testing, and environmental monitoring of manufacturing facilities.
• Analytical Testing: Comprehensive analytical testing is performed on each batch of API. This includes identity testing (e.g., using Infrared Spectroscopy, Mass Spectrometry), purity assays (e.g., High-Performance Liquid Chromatography - HPLC), determination of residual solvents (Gas Chromatography - GC), heavy metal content, and microbial limits.
• Stability Studies: API manufacturers conduct stability studies to determine the shelf-life and appropriate storage conditions for Midodrine Hydrochloride API. These studies involve exposing the API to various temperature and humidity conditions over extended periods.

The complexity and regulatory demands of API production mean that only specialized chemical manufacturers with proven track records in pharmaceutical ingredient synthesis can effectively produce Midodrine Hydrochloride.

WHICH COMPANIES PROVIDE FORMULATION AND FINISHED DOSAGE FORM MANUFACTURING FOR MIDODRINE HYDROCHLORIDE?

The formulation and manufacturing of finished dosage forms for Midodrine Hydrochloride involve companies with capabilities in tablet production, packaging, and regulatory dossier submission. These entities often work as contract manufacturing organizations (CMOs) or are integrated pharmaceutical companies with their own formulation divisions. The primary dosage form for Midodrine Hydrochloride is oral tablets, typically available in strengths of 2.5 mg and 5 mg.

Key players in this segment include:

• Major Generic Pharmaceutical Companies: Companies that market generic versions of Midodrine Hydrochloride (e.g., Midodrine HCl tablets by various brands) are involved in the formulation and manufacturing. These can include large multinational corporations with broad generic portfolios and smaller, specialized generic drug manufacturers. Examples include Teva Pharmaceutical Industries Ltd., Apotex Inc., and Par Pharmaceutical (an Endo International Company), which have historically had Midodrine HCl products in their portfolios.
• Contract Manufacturing Organizations (CMOs): A significant portion of finished dosage form manufacturing is outsourced to CMOs. These organizations specialize in taking an API and developing a stable, effective finished product. They offer services such as formulation development, process validation, commercial manufacturing, and packaging. Reputable CMOs with experience in solid oral dosage forms and regulatory compliance are sought after. Examples of CMOs that may be involved (depending on specific supply agreements) include Catalent Pharma Solutions and Recipharm AB, which have extensive global networks and broad manufacturing capabilities.
• Helsinn Healthcare S.A.: As mentioned previously, Helsinn is involved in the development and manufacturing of Midodrine Hydrochloride, including finished dosage forms, particularly for its proprietary product (Gutron® in some markets).

The selection of a formulation partner depends on factors such as manufacturing capacity, technological expertise in tablet compression and coating, quality assurance systems, regulatory track record, and cost-effectiveness. Companies must ensure their chosen CMO or internal facility meets the GMP requirements of the target markets.

WHAT IS THE REGULATORY STATUS AND COMPLIANCE REQUIRED FOR MIDODRINE HYDROCHLORIDE PRODUCTION?

The production and marketing of Midodrine Hydrochloride are governed by strict regulatory frameworks established by health authorities worldwide. Compliance is mandatory for all participants in the supply chain, from API manufacturers to finished dosage form producers.

Key regulatory aspects include:

• Active Substance Master File (ASMF) / Drug Master File (DMF): API manufacturers are typically required to submit an ASMF (in Europe) or a DMF (in the U.S.) to regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls (CMC) of the API. This allows regulatory bodies to review the API quality independently of the finished product application.
• Current Good Manufacturing Practices (cGMP): All manufacturing facilities involved in producing Midodrine Hydrochloride API and finished drug products must comply with cGMP guidelines. These guidelines cover aspects such as facility design, equipment qualification and maintenance, personnel training, raw material control, process validation, quality control testing, and record-keeping. Regulatory agencies conduct regular inspections to ensure compliance.
• Pharmaceutical Quality System (PQS): Companies must implement a robust PQS, which is a comprehensive system that encompasses all aspects of quality management. This includes change control, deviation management, corrective and preventive actions (CAPA), and risk management.
• Drug Product Registration: Finished dosage forms must undergo a rigorous review and approval process before they can be marketed. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) in the U.S., or a Marketing Authorisation Application (MAA) in Europe. These applications include extensive data on the drug product's efficacy, safety, and CMC.
• Pharmacopoeial Standards: Midodrine Hydrochloride must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These standards define the acceptable limits for identity, purity, assay, and other critical quality attributes.
• Post-Marketing Surveillance: Once approved, manufacturers are required to monitor the drug's performance in the market, report adverse events, and manage any quality issues that arise. This includes implementing pharmacovigilance systems.
• Impurity Profiling: Regulatory agencies increasingly focus on the control of impurities in APIs and finished drug products, including potential genotoxic impurities. Manufacturers must demonstrate robust impurity profiling and control strategies.

Adherence to these regulations is non-negotiable. Failure to comply can result in warning letters, import alerts, product recalls, and ultimately, the inability to market the drug.

WHAT ARE THE KEY SUPPLY CHAIN CHALLENGES FOR MIDODRINE HYDROCHLORIDE?

The supply chain for Midodrine Hydrochloride faces several challenges, stemming from its specialized nature, regulatory environment, and global manufacturing landscape. Addressing these challenges is crucial for ensuring consistent product availability and managing costs.

Key supply chain challenges include:

• Limited Number of API Manufacturers: As previously noted, the number of primary API manufacturers for Midodrine Hydrochloride is relatively small compared to more widely produced APIs. This concentration increases the risk of supply disruptions if a key manufacturer experiences production issues, regulatory shutdowns, or decides to exit the market.
• Raw Material Sourcing and Volatility: The synthesis of Midodrine Hydrochloride relies on specific chemical precursors. The availability and cost of these raw materials can be subject to global market fluctuations, geopolitical events, and the supply chain integrity of upstream suppliers. Any disruption in the raw material supply can directly impact API production.
• Quality Control and Regulatory Hurdles: Maintaining consistent quality across different manufacturing sites and ensuring ongoing compliance with evolving cGMP standards and pharmacopoeial requirements is a continuous challenge. Regulatory inspections and audits can lead to delays or require significant investment in remediation.
• Geographic Concentration of Manufacturing: A significant portion of API and finished dosage form manufacturing for many pharmaceuticals, including Midodrine Hydrochloride, is concentrated in specific geographic regions, particularly India and China. While this offers cost advantages, it also creates vulnerability to disruptions such as natural disasters, trade disputes, or public health crises (e.g., pandemics) that can impact production and global logistics.
• Logistics and Transportation: The global nature of the pharmaceutical supply chain requires robust logistics for transporting APIs and finished products. This includes specialized handling, temperature-controlled shipping for certain intermediates or finished products if required, and adherence to international shipping regulations. Delays in transit or customs can impact inventory levels and product availability.
• Intellectual Property and Market Entry: While Midodrine Hydrochloride itself is an older drug with no active patent protection for the molecule, there can be complexities related to process patents for specific manufacturing routes or formulation patents. For generic manufacturers, navigating the regulatory approval process and potential patent challenges from originators (even for older drugs) can be a barrier to entry or expansion.
• Forecasting and Demand Planning: Accurate forecasting of demand for a drug like Midodrine Hydrochloride, which serves a specific patient population, can be challenging. Inaccurate forecasting can lead to either overstocking and associated costs or understocking and potential drug shortages.

Effective supply chain management requires strong relationships with suppliers, dual-sourcing strategies where feasible, proactive risk assessment, and robust inventory management systems.

WHAT ARE THE GEOGRAPHICAL DISTRIBUTION PATTERNS OF MIDODRINE HYDROCHLORIDE MANUFACTURING?

The manufacturing of Midodrine Hydrochloride, encompassing both Active Pharmaceutical Ingredient (API) and finished dosage forms, exhibits a distinct geographical distribution pattern driven by cost efficiencies, regulatory expertise, and established pharmaceutical manufacturing infrastructure.

Key geographical patterns include:

• Asia (India and China): These countries are dominant hubs for API manufacturing globally, and Midodrine Hydrochloride is no exception. Numerous Indian and Chinese chemical synthesis companies produce the API, often at competitive price points. Their large-scale production capabilities and established expertise in complex organic synthesis make them primary sources for the global market. Finished dosage form manufacturing also occurs in these regions, with many generic drug companies producing tablets for both domestic and international distribution.
• Europe: European countries, particularly those with strong pharmaceutical manufacturing bases like Italy and Switzerland, host significant players. Companies like Helsinn Healthcare S.A. (Switzerland) are known for their involvement in Midodrine Hydrochloride. Euticals (Italy, now part of Wockhardt) has also been a key player. European manufacturing often emphasizes high regulatory standards and specialized production capabilities.
• North America (United States and Canada): While a significant portion of API and some finished dosage form manufacturing has moved overseas, North America remains a critical market and also has domestic manufacturing capabilities, particularly for finished products by generic drug companies and contract manufacturers. Companies like Teva Pharmaceutical Industries (with operations in the U.S.) and others operate within this region. Regulatory proximity and rapid market access are key advantages for manufacturing within North America.

The distribution pattern is dynamic, influenced by economic factors, trade policies, and the strategic decisions of multinational pharmaceutical companies. Companies often maintain a diversified supplier base across these regions to mitigate risks associated with single-region dependency.

WHAT ARE THE KEY DRIVERS AND TRENDS IN THE MIDODRINE HYDROCHLORIDE SUPPLY CHAIN?

The supply chain for Midodrine Hydrochloride is influenced by several key drivers and trends shaping the broader pharmaceutical industry. These factors impact manufacturing strategies, sourcing decisions, and overall market dynamics.

Key drivers and trends include:

• Genericization and Cost Pressure: Midodrine Hydrochloride is an established drug with no market exclusivity for the molecule itself. This leads to significant price pressure from generic competition. Manufacturers are driven to optimize production costs through efficient synthesis, economies of scale, and sourcing from regions with lower manufacturing expenses.
• Regulatory Scrutiny and Compliance Demands: Increasing global regulatory expectations regarding API quality, impurity control, and manufacturing practices (cGMP) are a major driver. Companies must invest heavily in quality systems and compliance to meet standards set by agencies like the FDA, EMA, and others. This necessitates robust validation processes and continuous monitoring.
• Supply Chain Resilience and Risk Mitigation: Recent global events have highlighted the fragility of pharmaceutical supply chains. There is a growing trend towards building resilience through measures like dual-sourcing, near-shoring or reshoring critical manufacturing steps where economically viable, and enhanced supply chain visibility. Companies are actively assessing geopolitical risks, natural disaster impacts, and logistical vulnerabilities.
• Technological Advancements in Chemical Synthesis: While Midodrine Hydrochloride synthesis is established, ongoing research in process chemistry can lead to more efficient, environmentally friendly, and cost-effective manufacturing routes. Companies are exploring novel synthetic pathways and purification techniques to improve yields and reduce waste.
• Sustainability and Environmental Considerations: The pharmaceutical industry is increasingly focusing on sustainability. This translates to a demand for greener manufacturing processes, reduced solvent usage, and better waste management throughout the Midodrine Hydrochloride supply chain.
• Focus on Data Integrity and Digitalization: Regulatory bodies are emphasizing data integrity in all aspects of manufacturing and quality control. The adoption of digital technologies, such as electronic batch records and laboratory information management systems (LIMS), is becoming crucial for ensuring data accuracy, traceability, and regulatory compliance.
• Outsourcing to CMOs/CDMOs: The trend of outsourcing manufacturing activities to Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) continues. Pharmaceutical companies leverage the specialized expertise, flexibility, and capital efficiency offered by these partners for both API and finished dosage form production.

These drivers collectively shape the strategic priorities for companies involved in the Midodrine Hydrochloride market, pushing for efficiency, quality, and robustness in their supply chains.

KEY TAKEAWAYS

• Midodrine Hydrochloride API manufacturing is concentrated among a limited number of specialized chemical synthesis companies, with significant presence in India and China.
• Finished dosage form manufacturing is primarily carried out by generic pharmaceutical companies and contract manufacturing organizations (CMOs) globally.
• Strict adherence to Current Good Manufacturing Practices (cGMP) and pharmacopoeial standards is mandatory for all API and finished product manufacturers.
• Key supply chain challenges include the limited number of API suppliers, raw material volatility, and navigating complex global regulatory requirements.
• Geographical manufacturing distribution favors Asia for API production, with significant finished product manufacturing also occurring in Asia, Europe, and North America.
• The supply chain is driven by genericization, intense cost pressures, increasing regulatory scrutiny, and a growing emphasis on supply chain resilience and sustainability.

FREQUENTLY ASKED QUESTIONS

1. What is the typical lead time for sourcing Midodrine Hydrochloride API from major manufacturers?

Typical lead times for sourcing Midodrine Hydrochloride API can range from 8 to 20 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory. Expedited options may be available at a premium.

2. How are impurities in Midodrine Hydrochloride API controlled and monitored?

Impurities are controlled through stringent process validation, optimization of reaction conditions, and rigorous purification techniques. Monitoring involves comprehensive analytical testing using methods like High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) to identify and quantify known and unknown impurities against pharmacopoeial limits and ICH guidelines.

3. Are there any specific storage conditions required for Midodrine Hydrochloride API?

Midodrine Hydrochloride API is typically stored under controlled room temperature conditions, protected from light and moisture, to maintain its stability and prevent degradation. Specific recommendations are detailed in the manufacturer's Certificate of Analysis (CoA) and stability data.

4. What is the impact of regulatory inspections on Midodrine Hydrochloride supply?

Regulatory inspections (e.g., by FDA or EMA) can lead to temporary disruptions if a facility is found to be non-compliant. Remediation efforts may pause production, potentially impacting supply timelines. Successful inspections are crucial for continued market access.

5. Can a pharmaceutical company use multiple suppliers for Midodrine Hydrochloride API?

Yes, pharmaceutical companies often qualify and utilize multiple suppliers for Midodrine Hydrochloride API to ensure supply chain redundancy and mitigate risks associated with single-source dependency. This requires rigorous qualification of each new supplier to ensure consistent quality and regulatory compliance.

CITATIONS

[1] Euticals S.p.A. Company Overview. (n.d.). Retrieved from official business directories and historical pharmaceutical news archives.

[2] Helsinn Healthcare S.A. Product Portfolio. (n.d.). Retrieved from company website and regulatory filings.

[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from FDA website.

[4] European Medicines Agency. (n.d.). Active Substance Master Files (ASMFs). Retrieved from EMA website.

[5] United States Pharmacopeia. (n.d.). Midodrine Hydrochloride Monograph. United States Pharmacopeia–National Formulary.

[6] European Pharmacopoeia. (n.d.). Midodrine Hydrochloride Monograph. European Pharmacopoeia.

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ICH website.